Trial
NCT05971602
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gates Medical Research Institute
Collaborators
Global Alliance for TB Drug Development; Janssen Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd.
Condition
Pulmonary Tuberculosis
Intervention
Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
Why stopped
Data generated in the Gates MRI-TBD06-201 trial do not support the investigational regimens being able to achieve the trial objective of identifying a new regimen to treat tuberculosis in 3 months or less.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-20